Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, has appointed Emily Conley, Ph.D., Chief Executive Officer of Federation Bio, to its Board of Directors.

As the CEO of Federation Bio, Dr. Conley is pioneering the development of engineered bacterial-cell therapies to treat a wide range of diseases, from metabolic disorders to cancer. Prior to joining Federation Bio, Dr. Conley spent over a decade at 23andMe, where, as employee 30, she was instrumental in driving the strategic evolution of the company from a fee-for-service play into a drug development organization.

She has received numerous awards and honors during her career, including selection to Endpoints News’ 20 Biopharma Leaders Under 40, Business Insider’s 30 Leaders Under 40, and Google Ventures’ 25 Women Shaping the Future of Technology. Prior to joining 23andMe, Dr. Conley was a research fellow at the National Institutes of Health and is co-author of more than 35 academic publications. She received her doctorate in neuroscience from Stanford University School of Medicine, after earning a B.A. in psychology and business from Vanderbilt University. In addition to her recent appointment at Nuvalent, Dr. Conley serves on the boards of Medrio and TMRW Biosciences.

See Nuvalent’s press release here